Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

FX201

Phase 1Biologic

Pacira Pharmaceuticals, Inc

FX201 is one of 46 biologic programs targeting Osteoarthritis, Knee. It is currently in Phase 1.

1

Indications

1

Total Trials

1

Active Trials

45

Competitors

Pipeline

Status by Indication[3][1]

Indication

Osteoarthritis, KneeActive, not recruiting

Osteoarthritis, KneePhase 1

Active, not recruiting

Competition

Competitive Landscape

47 competitors in Osteoarthritis, Knee

#DrugCompanyPhaseTrials

Epidiolex

Jazz Pharmaceuticals

Voltaren

Cymbalta

Jazz Pharmaceuticals

Medrol

Colcrys

Jazz Pharmaceuticals

Aleve

Jazz Pharmaceuticals

Plaquenil

Jazz Pharmaceuticals

Calciferol

Jazz Pharmaceuticals

Marinol

Jazz Pharmaceuticals

Cyklokapron

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Active, not recruiting

Osteoarthritis, Knee

NCT04119687

Clinical

Trials by Indication[1]

Osteoarthritis, Knee1 trial

An Open-Label, Single Ascending Dose Study to Assess the Safety and Tolerability of FX201 in Patients With Osteoarthritis of the Knee

Active, not recruiting· Pacira Pharmaceuticals, Inc logo

Pacira Pharmaceuticals, Inc·Phase 1·NCT04119687·72 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for FX201. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — FX201 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for FX201. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Pacira Pharmaceuticals, Inc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: Pacira Pharmaceuticals, Inc

Related News